Celcuity Inc. (FRA:7VR)
Germany · Delayed Price · Currency is EUR | Market Cap | 3.81B +100.8% |
| Revenue (ttm) | n/a |
| Net Income | -198.24M |
| EPS | -3.78 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 93.50 |
| Previous Close | 85.00 |
| Day's Range | 93.50 - 93.50 |
| 52-Week Range | 11.48 - 127.00 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 13, 2026 |
About Celcuity
Celcuity Inc., a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company’s lead drug candidate includes Gedatolisib, which selectively targets various Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2 to treat patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) or HR+/HER2-, advanced or metastatic... [Read more]
News
Celcuity price target raised to $175 from $165 at Guggenheim
Guggenheim analyst Brad Canino raised the firm’s price target on Celcuity (CELC) to $175 from $165 and keeps a Buy rating on the shares. Celcuity remains well positioned ahead of…
Celcuity reports Q2 EPS ($1.07), consensus ($1.16)
“Celcuity (CELC) made monumental progress these past few months, achieving critical clinical and regulatory milestones related to gedatolisib. With the FDA approval of REVTORPYK, positive results from...
Celcuity price target lowered to $150 from $175 at Stifel
Stifel lowered the firm’s price target on Celcuity (CELC) to $150 from $175 and keeps a Buy rating on the shares. Management reiterated confidence in its ability to begin shipping…
Celcuity price target lowered to $140 from $157 at Needham
Needham lowered the firm’s price target on Celcuity (CELC) to $140 from $157 and keeps a Buy rating on the shares after its Q2 results and company’s updates following Revtorpyk’s…
Celcuity Earnings Call Transcript: Q2 2026
FDA approved REVTORPYK for HR-positive, HER2-negative advanced breast cancer, with commercial launch set for late Q3 2026 and a $6B+ U.S. market opportunity. Q2 net loss widened due to launch investments, but cash reserves are strong following a $575M convertible note.
Celcuity Earnings release: Q2 2026
Celcuity released its Q2 2026 earnings on August 13, 2026, summarizing the period's financial results.
Celcuity Quarterly report: Q2 2026
Celcuity has published its Q2 2026 quarterly earnings report on August 13, 2026.
Celcuity Inc. Reports Release of Second Quarter 2026 Financial Results and Provides Corporate Update
MINNEAPOLIS, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a biotechnology company focused on developing and commercializing targeted therapies for the treatment of multiple solid tu...
Celcuity Schedules Release of Second Quarter 2026 Financial Results and Webcast/Conference Call
MINNEAPOLIS, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a commercial-stage biotechnology company focused on developing and commercializing targeted therapies for the treatment of ...
CELC Investors Have Opportunity to Join Celcuity Inc. Fraud Investigation with SBS Law
LOS ANGELES--(BUSINESS WIRE)---- $CELC--CELC Investors Have Opportunity to Join Celcuity Inc. Fraud Investigation with SBS Law.
Celcuity announces NCCN recommendation for Revtorpyk combination
Celcuity (CELC) announced that Revtorpyk in combination with fulvestrant, with or without palbociclib, is recommended by the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncol...
Newly FDA-Approved REVTORPYK™ (gedatolisib) Included in the National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines for HR+/HER2- Locally Advanced or Metastatic Breast Cancer
REVTORPYK (gedatolisib) in combination with fulvestrant, with or without palbociclib, listed as a preferred Category 1 regimen for second-line or subsequent treatment for tumors without a PIK3CA mutat...
Short Report: Bears book profits in Celcuity
Welcome to this week’s installment of “The Short Interest Report” – The Fly’s weekly recap of short interest trends among some of the most widely followed high-short-float stocks. Using the…
Celcuity price target raised to $178 from $171 at Craig-Hallum
Craig-Hallum raised the firm’s price target on Celcuity (CELC) to $178 from $171 and keeps a Buy rating on the shares. Celcuity’s Revtorpyk approval came in as expected with a…
Celcuity shares fall as delayed breast cancer drug launch eclipses first US FDA approval
Shares of Celcuity fell about 8% in premarket trading on Wednesday, as the delayed commercial launch of its newly approved breast cancer drug and treatment-tolerability concerns overshadowed the com...
Celcuity price target raised to $155 from $145 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Celcuity (CELC) to $155 from $145 and keeps a Buy rating on the shares following the FDA approval of Revtorpyk. Published first…
Celcuity price target raised to $177 from $160 at Citizens
Citizens raised the firm’s price target on Celcuity (CELC) to $177 from $160 and keeps an Outperform rating on the shares. Celcuity’s early FDA approval of Revtorpyk marks its transition…
Celcuity Transcript: FDA announcement
FDA approved REVTORPYK for HR-positive, HER2-negative, PIK3CA wild-type advanced breast cancer, based on strong Phase III data showing significant improvements in progression-free survival and a favorable safety profile. Commercial launch is planned for late Q3, with robust support and market adoption strategies.
Celcuity Press release: FDA announcement
Celcuity issued a press release on July 14, 2026, disclosing material business information to investors.
Celcuity Slides: FDA announcement
Celcuity has posted slides in relation to its latest quarterly earnings report, which was published on July 14, 2026.
Celcuity announces FDA approval of Revtorpyk
Celcuity (CELC) announced that the U.S. Food and Drug Administration approved REVTORPYK for the treatment of patients with hormone receptor positive, human epidermal growth factor receptor 2 negative,...
Celcuity Announces FDA Approval of REVTORPYK™ (gedatolisib) for the Treatment of HR+/HER2-, PIK3CA Wild-Type Locally Advanced or Metastatic Breast Cancer
MINNEAPOLIS, July 14, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a biotechnology company focused on developing and commercializing targeted therapies for multiple solid tumor indications, ...
Celcuity Slides: Corporate presentation
Celcuity has posted slides in relation to its latest quarterly earnings report, which was published on July 14, 2026.